Oxford BioMedica PLC (OXBDF)

[marcusl2]

The way I see it we now have a platform of off-the-shelf CAR-NK in a similar way Cellectis have off the shelf Car-t. Has to be good news if it all works out. The NK also can treat auto-immune diseases like AIDS if I understand it correctly.


The attached videos have helped me understand NK cells. Green Cross have completed phase II on their lead product MG4101. It is a cell therapy product, which separates NK cells from peripheral blood of healthy donors and grows them in order to treat tumors. Unlike conventional anti-cancer immune cell treatments, which treat cancer with NK cells from patients or living-related donors, such as parents and children, the product contains healthy NK cells from other people. - See more at:HTTP://www.businesskorea.co.kr/english/news/industry/13563-cancer-treatment-green-cross-accelerates-nk-cell-based-therapy-commercialization#sthash.kQfjoWkA.dpuf

the NK cell works much like an ideal drug: effective and nontoxic.
HTTP://www.ciml.univ-mrs.fr/science/lab-eric-vivier/home

NK cells are a type of immune cells which prevent cancer by destroying cancer cells and abnormal cells in the body. A healthy body produces 40 billion of NK cells a day. Out of 40 billion, there are about 400 mutant cells which can develop into cancer. Usually, NK cells in the body kill mutant cells, but a person can develop cancer when the number of mutant cells increases faster than that.

This is why NK cell treatments have come out. However, it is difficult to increase NK cells outside the body. For commercialization, it is vital to constantly manage the ability to kill cancer cells and the cell survival rate, and prevent bacterial and virus infections.

Hwang Yu-Kyeong, managing director at Green Cross Lab Cell, said, “Using immune cells from healthy donors, MG4101 is a novel immune cell therapy, which can be supplied regularly and improve curative power without immune side effects. The company has improved the competitiveness of the product with large-scale culture and cryopreservation technologies for commercialization.”